eQcell Inc.

eQcell™ Inc. is Canada’s premier clinical-stage regenerative medicine company. Founded by Dr. Thomas Koch, Assistant Professor at Canada's University of Guelph, his work reflects 15 years of stem cell research and some $6 million of research investment. The company's target is regenerative therapies for human health utilizing the pathway of conditions and diseases affecting sporting and companion animals globally for which current treatments are ineffective, not fully effective, or palliative. eQcell has developed allogeneic equine cord blood stem cells, for which Dr. Koch published the world's first paper, and is producing canine adipose-derived mesenchymal stromal cells to provide novel therapeutic options. eQcell’s initial concentration in veterinary therapy is designed to most rapidly achieve marketing approval for its veterinary regenerative stem cells, in the process generating data leading to a scientifically and economically-effective pathway for translation into similar human applications. eQcell is a leader in the now-established science bridging development of therapeutics for both humans and animal health.